drugset / Trial / NCT06517199

Olanzapine for Cancer Related Anorexia-cachexia Syndrome

NCT06517199

Phase 3 Recruiting 138 enrolled Mahidol University
RandomizedParallel-groupTriple-blindTreatment

Summary

Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.

Timeline

Start
2024-01-22
Primary completion
2026-01-21
Completion
2026-01-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Olanzapine Small molecule 2.5 mg
Comparator Olanzapine Small molecule 5 mg

Indications